Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics Inc (NQ: NRIX )

10.92 +0.75 (+7.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 272,544
Open 10.37
Bid (Size) 10.80 (1)
Ask (Size) 12.14 (1)
Prev. Close 10.17
Today's Range 10.14 - 11.07
52wk Range 8.340 - 19.91
Shares Outstanding 47,147,781
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Nurix Therapeutics
 
Via Benzinga
JPMorgan, Citigroup, QuidelOrtho And Other Big Stocks Moving Higher On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga

Performance

YTD
+0.65%
+0.65%
1 Month
+15.31%
+15.31%
3 Month
+21.87%
+21.87%
6 Month
-11.79%
-11.79%
1 Year
+3.31%
+3.31%

More News

Read More
Nurix Therapeutics Inc. (NASDAQ: NRIX) Highlighted for Surprising Price Action
Via Investor Brand Network
Expert Ratings for Nurix Therapeutics
Via Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Analyst Ratings for Nurix Therapeutics
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Overview
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Via InvestorPlace
Where Nurix Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings for Nurix Therapeutics
Via Benzinga
CSX, Veris Residential And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month — Also Adds Stake In This Biopharma Company
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
Via Talk Markets
Tesla, Twitter And 76 Biggest Movers From Friday
Via Benzinga
Why Nurix Therapeutics Shares Are Rising Today
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
69 Biggest Movers From Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.